LOSS OF AMPLIFIED EGFR GENE WITH MUTATION AS A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO EGFR-TKIS IN EGFR MUTATED NSCLC CELLS

被引：0
|
作者：
Furugaki, K. [1 ]
Iwai, T. [1 ]
Moriya, Y. [1 ]
Fujimoto-Ouchi, K. [2 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Prod Res Dept, Kamakura, Kanagawa, Japan
[2] Chugai Pharmaceut Co Ltd, Discovery Pharmacol Dept, Kamakura, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：390 / 391
页数：2
相关论文
共 50 条
  • [21] Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
    Feng, W.
    Gu, W.
    Zhang, H.
    Lu, Y.
    Gu, W.
    Li, M.
    Yang, S.
    Zhang, J.
    Ye, Z.
    Lin, Q.
    Liang, Y.
    Chen, H.
    Cheng, Y.
    Yao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
  • [22] Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
    Wu, Wen-Shuo
    Chen, Yuh-Min
    JOURNAL OF PERSONALIZED MEDICINE, 2014, 4 (03) : 297 - 310
  • [23] Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
    Tudor, Roxana Aline
    D'Silva, Adrijana
    Tremblay, Alain
    MacEachern, Paul
    Morris, Don
    Brenner, Darren
    Kopciuk, Karen
    Bebb, Dafydd Gwyn
    PLOS ONE, 2017, 12 (08):
  • [24] Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Goto, Koichi
    Matsumoto, Shingo
    Umemura, Shigeki
    Niho, Seiji
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] The Monitoring of Mutated EGFR Levels in Liquid Biopsy from Patients on EGFR-TKIs - Early Detection of NSCLC Progression
    Szpechcinski, A.
    Bryl, M.
    Czyzewicz, G.
    Wojda, E.
    Szwiec, M.
    Swiniuch, D.
    Rudzinski, S.
    Duk, K.
    Ramlau, R.
    Sliwinski, P.
    Barinow-Wojewodzki, A.
    Chorostowska-Wynimko, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S421 - S421
  • [26] Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
    Wang, Bao-Xiao
    Ou, Wei
    Mao, Xiao-Yong
    Liu, Zui
    Wu, Hui-Qi
    Wang, Si-Yu
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 160 : 96 - 100
  • [27] Evolving therapeutic landscape of EGFR-TKIs in NSCLC
    Feng, Chenfeina
    Li, Rendong
    Li, Xiaolei
    Xu, Xinping
    MCB Molecular and Cellular Biomechanics, 2024, 21
  • [28] Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression
    Kobayashi, Kenichi
    Seike, Masahiro
    Zou, Fenfei
    Noro, Rintaro
    Chiba, Mika
    Ishikawa, Arimi
    Kunugi, Shinobu
    Kubota, Kaoru
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2018, 38 (02) : 753 - 762
  • [29] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    ONCOTARGET, 2016, 7 (41): : 66480 - 66490
  • [30] Intratumoral heterogeneity and EGFR-TKIs resistance
    Zhou, Caicun
    Cai, Weijing
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S15 - S15
12345